Quick Answer
NeuroSense Therapeutics Ltd. reported Diluted EPS of $0.44 per share (loss) for fiscal year 2025.
NeuroSense Therapeutics Ltd. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.44 | +18.5% |
| 2024 | -$0.54 | +27.0% |
| 2023 | -$0.74 | +18.7% |
| 2022 | -$0.91 | — |
- NeuroSense Therapeutics Ltd. showed an increase of +18.5% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, NeuroSense Therapeutics Ltd.’s diluted eps has grown by 51.6% (from $0.91 per share (loss) to $0.44 per share (loss)).
- The most recent figure is from NeuroSense Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: